Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF165b Isoform in the Vitreous of Patients with Retinopathy of Prematurity  

作　　者：Min Zhao 

机构地区：[1]Department of Ophthalmology, Peking University People's Hospital, Beijing 100044, China [2]Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100044, China [3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China

出　　处：《Chinese Medical Journal》2015年第18期2505-2509,共5页中华医学杂志（英文版）

摘　　要：Background： This study was to examine the expression of total vascular endothelial growth factor （VEGF） and the anti-angiogenic VEGF165b isoform in the vitreous body ofretinopathy of prematurity （ROP） patients, and to further study the role of the VEGF splicing in the development of ROP. Methods： This was a prospective clinical laboratory investigation study. All patients enrolled received standard ophthalmic examination with stage 4 ROP that required vitrectomy to collect the vitreous samples. The control samples were from congenital cataract patients. The expression of total VEGF and the anti-angiogenic VEGF165b were measured by enzyme-linked immunosorbent assay. Results were analyzed statistically using nonparametric tests. Results： The total VEGF level was markedly elevated in ROP samples while VEGF165b was markedly decreased compared to control group. The relative protein expression level ofVEGF165b isoform was significantly decreased in ROP patients which were correlated with the ischemia-induced neovascularization. Conclusions： There was a switch of VEGF splicing from anti-angiogenic to pro-angiogenic family in ROP patients. A specific inhibitor that more selectively targets VEGF165 and controls the VEGF splicing between pro- and anti-angiogenic families might be a more effective therapy for ROP.Background： This study was to examine the expression of total vascular endothelial growth factor （VEGF） and the anti-angiogenic VEGF165b isoform in the vitreous body ofretinopathy of prematurity （ROP） patients, and to further study the role of the VEGF splicing in the development of ROP. Methods： This was a prospective clinical laboratory investigation study. All patients enrolled received standard ophthalmic examination with stage 4 ROP that required vitrectomy to collect the vitreous samples. The control samples were from congenital cataract patients. The expression of total VEGF and the anti-angiogenic VEGF165b were measured by enzyme-linked immunosorbent assay. Results were analyzed statistically using nonparametric tests. Results： The total VEGF level was markedly elevated in ROP samples while VEGF165b was markedly decreased compared to control group. The relative protein expression level ofVEGF165b isoform was significantly decreased in ROP patients which were correlated with the ischemia-induced neovascularization. Conclusions： There was a switch of VEGF splicing from anti-angiogenic to pro-angiogenic family in ROP patients. A specific inhibitor that more selectively targets VEGF165 and controls the VEGF splicing between pro- and anti-angiogenic families might be a more effective therapy for ROP.

关 键 词：NEOVASCULARIZATION Retinopathy of Prematurity Vascular Endothelial Growth Factor VEGFxxx VEGFxxxb 

分 类 号：Q78[生物学—分子生物学] X773[环境科学与工程—环境工程]